59260 Federal Register / Vol. 69, No. 191 / Monday, October 4, 2004 / Notices 

purpose of this conference call is to 

provide technical assistance related to 

the CHGME PP.

DATES: The conference call will be held 

on Wednesday, October 20, 2004 from 

1:30 p.m. to 3:30 p.m. EST.

FOR FURTHER INFORMATION CONTACT:

Ayah E. Johnson, Ph.D., telephone: (301) 

443–1058; Division of Medicine and 

Dentistry, Bureau of Health Professions, 

Health Resources and Services 

Administration, Parklawn Building, 

5600 Fishers Lane, Room 9A–05, 

Rockville, Maryland 20857; or by e-mail 

at: ajohnson@hrsa.gov.

SUPPLEMENTARY INFORMATION: The 

CHGME PP, as authorized by section 

340E of the Public Health Service (PHS) 

Act (the Act) (42 U.S.C. 256e), provides 

funds to children’s hospitals to address 

disparity in the level of Federal funding 

for children’s hospitals that result from 

Medicare funding for graduate medical 

education (GME). Pub. L. 106–310 

amended the CHGME statute to extend 

the program through FY 2005. 

The statute authorized $280 million 

for both direct and indirect medical 

education payments in FY 2000, $285 

million in FY 2001, and for each of the 

FY 2002 through FY 2005 such sums as 

necessary. Congress appropriated $303 

million in FY 2004 for the CHGME PP. 

These funds have supported over 4,000 

residents receiving training in children’s 

teaching hospitals in 31 States. 

The agenda for the conference calls 

will include but not be limited to: (1) 

Welcome and opening comments; (2) 

news releases/updates; (3) reminders; 

and (4) ‘‘on the horizon’’ topics of 

interest. Time will also be available for 

a question and answer period. Agenda 

items will be determined as priorities 

dictate. 

Interested parties must register, in 

advance, but not later than 5 days prior 

to the scheduled conference call. 

Conference call registration forms and 

information about the Program can be 

found on the CHGME PP Web site. The 

Web site address is http://bhpr.hrsa.gov/

childrenshospitalgme.

Dated: September 28, 2004. 

Elizabeth M. Duke, 

Administrator.

[FR Doc. 04–22282 Filed 10–1–04; 8:45 am] 

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on Infant 

Mortality; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Public Law 92–463), notice is hereby 

given of the following meeting: 

Name: Advisory Committee on Infant 

Mortality (ACIM). 

Dates and Times: November 11, 2004, 

9 a.m.–5 p.m., November 12, 2004, 8:30 

a.m.–3 p.m. 

Place: The Latham Hotel, 3000 M 

Street, NW., Washington, DC 20007 

(202) 726–5000. 

Status: The meeting is open to the 

public. 

Purpose: The Committee provides 

advice and recommendations to the 

Secretary of Health and Human Services 

on the following: Department programs 

that are directed at reducing infant 

mortality and improving the health 

status of pregnant women and infants; 

factors affecting the continuum of care 

with respect to maternal and child 

health care, including outcomes 

following childbirth; strategies to 

coordinate the variety of Federal, State, 

local and private programs and efforts 

that are designed to deal with the health 

and social problems impacting on infant 

mortality; and the implementation of 

the Healthy Start program and Healthy 

People 2010 infant mortality objectives. 

Agenda: Topics that will be discussed 

include the following: Infant Mortality 

Differentials; Social Factors and Racial 

Disparities; and Perinatal Outreach 

Strategies. Agenda items are subject to 

change as priorities are further 

determined.

FOR FURTHER INFORMATION CONTACT:

Anyone requiring information regarding 

the Committee should contact Peter C. 

Van Dyck, M.D., M.P.H., Executive 

Secretary, ACIM, Health Resources and 

Services Administration (HRSA), Room 

18–05, Parklawn Building, 5600 Fishers 

Lane, Rockville, MD 20857, telephone: 

(301) 443–2170. 

Individuals who are interested in 

attending any portion of the meeting or 

who have questions regarding the 

meeting should contact Ann M. Koontz, 

C.N.M., Dr.P.H., HRSA, Maternal and 

Child Health Bureau, telephone: (301) 

443–6327.

Dated: September 29, 2004. 

Tina M. Cheatham, 

Director, Division of Policy Review and 

Coordination.

[FR Doc. 04–22283 Filed 10–1–04; 8:45 am] 

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on Training in 

Primary Care Medicine and Dentistry; 

Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Public Law 92–463), notice is hereby 

given of the following meeting:

Name: Advisory Committee on Training in 

Primary Care Medicine and Dentistry. 

Dates and Times: October 21, 2004, 8:15 

a.m.–4:30 p.m., October 22, 2004, 8 a.m.–2 

p.m. 

Place: The Hilton in Gaithersburg, 620 

Perry Parkway, Gaithersburg, Maryland 

20877. 

Status: The meeting will be open to the 

public. 

Purpose: The Advisory Committee 

provides advice and recommendations on a 

broad range of issues dealing with programs 

and activities authorized under section 747 

of the Public Health Service Act as amended 

by The Health Professions Education 

Partnership Act of 1998, Public Law 105–

392. At this meeting the Advisory Committee 

will work on its draft fifth report which will 

be submitted to Congress and the Secretary 

of the Department of Health and Human 

Services in November 2005 and which 

focuses on measuring outcomes of Title VII, 

section 747 grant programs. 

Agenda: The meeting on Thursday, 

October 21, will begin with opening 

comments from the Chair of the Advisory 

Committee. A plenary session will follow in 

which Advisory Committee members will 

hear speakers address the topic of outcomes 

measurement from various perspectives. The 

Advisory Committee will work on its fifth 

report, both in plenary session and in smaller 

workgroups. An opportunity will be 

provided for public comment. 

On Friday, October 22, the Advisory 

Committee will continue work on the report. 

An opportunity will be provided for public 

comment. 

For Further Information Contact: Anyone 

interested in obtaining a roster of members or 

other relevant information should write or 

contact Jerilyn K. Glass, M.D., Ph.D., Division 

of Medicine and Dentistry, Bureau of Health 

Professions, Health Resources and Services 

Administration, Room 9A–27, Parklawn 

Building, 5600 Fishers Lane, Rockville, 

Maryland 20857, Telephone (301) 443–6326. 

The web address for information on the 

Advisory Committee is http://bhpr.hrsa.gov/

medicine-dentistry/actpcmd.

Federal Register / Vol. 69, No. 191 / Monday, October 4, 2004 / Notices 59261

Dated: September 27, 2004. 

Tina M. Cheatham, 

Director, Division of Policy Review and 

Coordination.

[FR Doc. 04–22184 Filed 10–1–04; 8:45 am] 

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing

AGENCY: National Institutes of Health, 

Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing.

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Chromatography Apparatus and 

Method 

Yoichiro Ito (NHLBI) 

U.S. Provisional Application Filed 24 

Aug 2004 (DHHS Reference No. E–

277–2004/0–US–01) 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing for industrial 

scale-up production and commercial 

distribution is an improved 

countercurrent chromatography 

apparatus comprising a disk having a 

series of interconnected and elongated 

compartments coupled by ducts that 

form a portion of a groove in a surface 

of the disk. At least some of the 

elongated compartments have an aspect 

ratio of at least greater than two and a 

width greater than twice the width of 

the connecting ducts and a length of 

about 10 to 20 times the length of the 

connecting ducts. This apparatus may 

also be used for a large-scale industrial 

separation by coaxially rotating in 

centrifugal or gravitational fields.

HIV–1 Infection Detection Assay for 

Seroconverted HIV–1 Vaccine 

Recipients 

Hana Golding, Surender Khurana (FDA/

CBER) 

U.S. Provisional Application Filed 08 

Sep 2004 (DHHS Reference No. E–

259–2004/0–US–01) 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing and 

commercial distribution is an assay 

method and kit having diagnostic 

peptide fragments derived from human 

immunodeficiency virus-1 (HIV–1). The 

new serology assay includes HIV–1 

peptide fragments epitopes that map to 

HIV–1 GAG–p6, and gp41 genes. These 

epitopes are broadly reactive with early 

sera from HIV infected individuals, do 

not illicit protective antibodies, do not 

illicit immunologic cytotoxicity and are 

readily removable from current and 

future HIV–1 candidates. The assay is 

advantageous in detecting HIV–1 early 

breakthrough infections in 

seroconverted vaccine recipients while 

being able to distinguish between 

individuals with bonafide breakthrough 

infections versus non-HIV infected 

vaccine recipients presenting only 

vaccine borne antibodies. For example, 

90% of vaccine recipients receiving a 

Canarypox construct expressing a 

plurality of HIV antigens (Env, Gag, Pol, 

HIV Protease, Nef) followed by an 

envelope protein boost, scored positive 

in FDA licensed enzyme immunoassay, 

rapid test, and Western blot (MartaLouise Ackers et al., J Infect Dis. 

187:879 (2003)). Such seroconversion 

has a negative impact on phase III 

efficacy trials of prophylactic HIV 

vaccines that require early detection of 

breakthrough infections and also 

exclude non-HIV infected vaccine 

recipients from the pool of potential 

blood donors.

Flow-Through, Thermal-ExpansionCompensated Microcells for Analytical 

Transmission Infrared and Other Light 

Spectroscopies 

Edward Mertz (NICHD), James Sullivan 

(ORS) 


EN04OC04.040</GPH>